Photo of Dennis Bourdette, M.D., F.A.A.N.

Dennis Bourdette M.D., F.A.A.N.

    • Professor of Neurology School of Medicine
    • Dr.Roy and Eulalia Swank family research professor Neurology School of Medicine
    • Director OHSU Multiple Sclerosis Center School of Medicine
    • Neuroscience Graduate Program School of Medicine

Dr. Bourdette is chair of the Department of Neurology, Roy and Eulalia Swank family research professor, executive director of the OHSU Multiple Sclerosis Center and co-director of the VA MS Center of Excellence-West. He directs a team dedicated to curing and treating diseases such as multiple sclerosis, Alzheimer’s, Parkinson’s, stroke, and ALS.

He is nationally recognized for his important discoveries in the field of multiple sclerosis and oversees an annual research budget of over $2 million. His team has attracted grants from the National Institutes of Health, Department of Veterans Affairs, National MS Society, Nancy Davis Foundation for Multiple Sclerosis, to name a few. He and his colleagues have received international attention for their development of a TCR peptide vaccine called Neurovax for the treatment of multiple sclerosis and a new therapy called VG1000 being developed with a local biotechnology company, Virogenomics. Dr. Bourdette received his medical degree at the University of California at Davis, joined OHSU in 1984 as a resident in the Department of Neurology.

Read more

Education

  • M.D., University of California-Davis Medical School 1978
  • Residency:

    • Medicine – Santa Clara Valley Medical Center, San Jose
    • Neurology – Oregon Health & Science University
  • Fellowship:

    • Neuroimmunology – Veterans Affairs Medical Center, Portland

Memberships and associations

  • American Board of Neurology and Psychiatry, 1985

Publications

  • "Sleep and its associations with perceived and objective cognitive impairment in individuals with multiple sclerosis." Journal of Sleep Research In: , Vol. 26, No. 4, 01.08.2017, p. 428-435.
  • "Author response : Neurologists and the economics of MS treatment: Lighting candles, not cursing the darkness." Neurology In: , Vol. 89, No. 5, 01.08.2017, p. 520-521.
  • "MS and bone marrow transplant : Not for most patients." Neurology  In: , Vol. 88, No. 22, 30.05.2017, p. e219.
  • "About multiple sclerosis and hematopoietic stem cells in the treatment of multiple sclerosis." Neurology  In: , Vol. 88, No. 22, 30.05.2017, p. e220.
  • "Ester-to-amide rearrangement of ethanolamine-derived prodrugs of sobetirome with increased blood-brain barrier penetration." Bioorganic and Medicinal Chemistry In: , Vol. 25, No. 10, 15.05.2017, p. 2743-2753.
  • "Sex-dependent treatment of chronic EAE with partial MHC class II constructs." Journal of Neuroinflammation In: , Vol. 14, No. 1, 100, 06.05.2017.
  • "Early Fever As a Predictor of Paroxysmal Sympathetic Hyperactivity in Traumatic Brain Injury." Journal of Head Trauma Rehabilitation  In: , 05.01.2017.
  • "Lipoic acid in secondary progressive MS." Neurology: Neuroimmunology and NeuroInflammation  In: , Vol. 4, No. 5, 374, 2017.
  • "Lipoic acid pharmacokinetics at baseline and 1 year in secondary progressive MS." Neurology: Neuroimmunology and NeuroInflammation  In: , Vol. 4, No. 5, 380, 2017.
  • "Rituximab for treating multiple sclerosis." Neurology  In: , Vol. 87, No. 20, 15.11.2016, p. 2070-2071.
  • "Neurologists and the economics of MS treatment : Lighting candles, not cursing the darkness." Neurology  In: , Vol. 87, No. 15, 11.10.2016, p. 1532-1533.
  • "The contemporary spectrum of multiple sclerosis misdiagnosis." Neurology In: , Vol. 87, No. 13, 27.09.2016, p. 1393-1399.
  • "Low-fat, plant-based diet in multiple sclerosis : A randomized controlled trial." Multiple Sclerosis and Related Disorders  In: , Vol. 9, 01.09.2016, p. 80-90.
  • "US health insurance is an obstacle to disease-modifying treatments in MS." Neurology  In: , Vol. 87, No. 4, 26.07.2016, p. 346-347.
  • "Dimethyl fumarate activates the prostaglandin EP2 receptor and stimulates cAMP signaling in human peripheral blood mononuclear cells." Biochemical and Biophysical Research Communications  In: , Vol. 475, No. 1, 17.06.2016, p. 19-24.
  • "Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients." Neurology: Clinical Practice In: , Vol. 6, No. 2, 01.04.2016, p. 177-182.
  • "Spatio-temporal patterns of demyelination and remyelination in the cuprizone mouse model." PLoS One  In: , Vol. 11, No. 4, e0152480, 01.04.2016.
  • "Immunopathology of Japanese macaque encephalomyelitis is similar to multiple sclerosis." Journal of Neuroimmunology In: , Vol. 291, 15.02.2016, p. 1-10.
  • "Omega-3 fatty acids for depression in multiple sclerosis : A randomized pilot study." PLoS One  In: , Vol. 11, No. 1, e0147195, 01.01.2016.
  • "Lipoic acid reduces inflammation in a mouse focal cortical experimental autoimmune encephalomyelitis model." Journal of Neuroimmunology  In: , Vol. 289, 15.12.2015, p. 68-74.
  • "Equivalence of glatiramer acetate generics with branded glatiramer acetate in efficacy and cost for the treatment of multiple sclerosis." JAMA Neurology  In: , Vol. 72, No. 12, 01.12.2015, p. 1411-1413.
  • "Erratum : Equivalence of glatiramer acetate generics with branded glatiramer acetate in efficacy and cost for the treatment of multiple sclerosis (JAMA Neurol. (2015) 1-3 10.1001/jamaneurol.2015.2605)." JAMA Neurology In: , Vol. 72, No. 12, 01.12.2015, p. 1537.
  • "Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic : Phase I single group and phase II randomized placebo-controlled studies." Journal of the neurological sciences  In: , Vol. 358, No. 1-2, 15.11.2015, p. 46-52.
  • "The cost of multiple sclerosis drugs in the US and the pharmaceutical industry : Too big to fail?" Neurology  In: , Vol. 85, No. 19, 10.11.2015, p. 1727-1728.
  • "Author response." Neurology In: , Vol. 85, No. 19, 10.11.2015, p. 1727.
  • "Author response." Neurology In: , Vol. 85, No. 19, 10.11.2015, p. 1728.
  • "Cognitive Impairment and Community Integration Outcomes in Individuals Living With Multiple Sclerosis." Archives of Physical Medicine and Rehabilitation In: , Vol. 96, No. 11, 01.11.2015, p. 1973-1979.
  • "Natalizumab to fingolimod : Questions answered, unanswered, and unasked." Neurology  In: , Vol. 85, No. 1, 07.07.2015, p. 14-15.
  • "Mapping human brain capillary water lifetime : High-resolution metabolic neuroimaging." NMR in Biomedicine In: , Vol. 28, No. 6, 01.06.2015, p. 607-623.
  • "The cost of multiple sclerosis drugs in the US and the pharmaceutical industry." Neurology In: , Vol. 84, No. 21, 26.05.2015, p. 2185-2192.

Additional information

Edit profile